B.P. v. Ramesh Balwani

CourtCourt of Appeals for the Ninth Circuit
DecidedSeptember 8, 2021
Docket20-15974
StatusUnpublished

This text of B.P. v. Ramesh Balwani (B.P. v. Ramesh Balwani) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
B.P. v. Ramesh Balwani, (9th Cir. 2021).

Opinion

FILED NOT FOR PUBLICATION SEP 8 2021 UNITED STATES COURT OF APPEALS MOLLY C. DWYER, CLERK U.S. COURT OF APPEALS

FOR THE NINTH CIRCUIT

B.P., on behalf of themselves and all No. 20-15974 others similarly situated; et al., D.C. Nos. 2:16-cv-02138-HRH Plaintiffs-Appellees, 2:16-cv-2373-HRH 2:16-cv-2660-HRH v. 2:16-cv-2775-HRH 2:16-cv-3599-HRH RAMESH BALWANI,

Defendant-Appellant, MEMORANDUM*

and

WALGREENS BOOTS ALLIANCE, INC.; WALGREENS ARIZONA DRUG COMPANY,

Defendants.

B.P., on behalf of themselves and all No. 20-15976 others similarly situated; et al., D.C. Nos. 2:16-cv-02138-HRH Plaintiffs-Appellees, 2:16-cv-2373-HRH 2:16-cv-2660-HRH v. 2:16-cv-2775-HRH 2:16-cv-3599-HRH WALGREENS BOOTS ALLIANCE, INC.; WALGREENS ARIZONA DRUG

* This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3. COMPANY,

Defendants-Appellants,

RAMESH BALWANI,

Defendant.

Appeal from the United States District Court for the District of Arizona H. Russel Holland, Senior District Judge, Presiding

Argued and Submitted August 9, 2021 San Francisco, California

Before: SILER,** CHRISTEN, and FORREST, Circuit Judges.

Defendants appeal the district court’s order granting class certification as to

plaintiffs’ claims pursuant to the Arizona Consumer Fraud Act (CFA), California’s

Unfair Competition Law, California’s False Advertising Law, racketeering in

violation of 18 U.S.C. § 1962(c), battery, and medical battery. We review a district

court’s class-certification order for abuse of discretion. Pulaski & Middleman,

LLC v. Google, Inc., 802 F.3d 979, 984 (9th Cir. 2015). We have jurisdiction

pursuant to 28 U.S.C. § 1292(e) and Federal Rule of Civil Procedure 23(f), and we

** The Honorable Eugene E. Siler, United States Circuit Judge for the U.S. Court of Appeals for the Sixth Circuit, sitting by designation. 2 affirm in part, reverse in part, and remand. Because the parties are familiar with

the facts, we do not recite them here.

1. Walgreens argues the district court erred by finding that the named

plaintiffs adequately represented absent class members’ claims because the named

plaintiffs dropped their emotional distress, retesting, and subsequent medical

treatment claims. See Fed. R. Civ. P. 23(a)(4). Walgreens argues the named

plaintiffs created a conflict of interest with absent class members by giving away

valuable theories of recovery that absent class members will be precluded from

raising in the future.

Conflicts of interest defeat legal adequacy where the interests of one

subclass “tug[] against” the interests of another. See Amchem Prods., Inc. v.

Windsor, 521 U.S. 591, 626 (1997). The district court reasoned that plaintiffs

voluntarily dismissed the emotional distress and subsequent medical treatment

claims for all class members, including themselves, because they concluded these

claims are not suitable for classwide resolution. The district court concluded that,

because of the disparity between litigation costs and the amount of recoverable

damage for any individual litigant, absent plaintiffs would likely be unable to

recover at all without class certification. The district court did not err by

concluding that plaintiffs dropped their emotional distress and subsequent medical

3 treatment claims for the strategic benefit of the entire class, and there is no conflict

of interest. Walgreens also argues that the district court “improperly passed the

resolution of this conflict on to the absent class members by relying solely on their

opt-out right” and failed to consider the value of absent class members’ dropped

claims. However, the district court did not make its adequacy determination solely

based on absent class members’ opt-out rights; it merely observed that absent class

members who wish to pursue them may opt out, and considered this as a factor in a

broader analysis. Therefore, we affirm the district court’s adequacy determination.

2. Defendant Balwani submits that the district court improperly

disregarded his defense when it made its predominance determination. Balwani

seeks to argue that certain plaintiffs received accurate test results and experienced

improved health outcomes, and they therefore did not suffer injury (i.e. they got

what they paid for).

This court has sometimes concluded that a class does not meet the

predominance requirement in cases where liability could be established only with

individualized evidence. See, e.g., Mazza v. Am. Honda Motor Co., 666 F.3d 581,

596 (9th Cir. 2012); Berger v. Home Depot USA, Inc., 741 F.3d 1061, 1069 (9th

Cir. 2014), abrogated on other grounds by Microsoft Corp. v. Baker, 137 S. Ct.

1702, 1712 (2017). Here, the district court determined that a single common issue

4 is central to plaintiffs’ case: whether Theranos and Walgreens’ blood testing

services were capable of producing reliable results. The district court concluded

that this issue predominates over individual questions of test result accuracy.

Balwani’s defense does not address this central issue of liability because whether

individual tests were in fact accurate is not relevant to representations that were

made concerning the reliability of the testing. Because “more important questions

apt to drive the resolution of the litigation are given more weight in the

predominance analysis over individualized questions which are of considerably

less significance,” Ruiz Torres v. Mercer Canyons Inc., 835 F.3d 1125, 1134 (9th

Cir. 2016), we conclude that the district court did not abuse its discretion by

finding predominance.

3. Walgreens argues the district court erred by certifying the battery and

medical battery claims because Walgreens employees did not touch all plaintiffs,

and determining who conducted any given plaintiff’s test is an individualized

inquiry that defeats predominance. Plaintiffs submit that Walgreens and Theranos

subjected them to offensive touching without consent on a classwide basis, and that

this claim can be established through common proof.

“An actor is subject to liability to another for battery if the actor

intentionally engages in an act that results in harmful or offensive contact with the

5 person of another.” Duncan v. Scottsdale Med. Imaging, Ltd., 70 P.3d 435, 439

(Ariz. 2003) (en banc) (citing Restatement (Second) of Torts §§ 13, 18 (1965)). To

make a classwide battery or medical battery claim, plaintiffs must be able to show

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
City of San Jose v. Price Waterhouse
990 F.2d 1256 (Ninth Circuit, 1993)
Mazza v. American Honda Motor Co., Inc.
666 F.3d 581 (Ninth Circuit, 2012)
Duncan v. Scottsdale Medical Imaging, Ltd.
70 P.3d 435 (Arizona Supreme Court, 2003)
Wyatt v. Wehmueller
806 P.2d 870 (Arizona Supreme Court, 1991)
Benjamin Berger v. Home Depot U.S.A., Inc.
741 F.3d 1061 (Ninth Circuit, 2014)
Pulaski & Middleman, LLC v. Google, Inc.
802 F.3d 979 (Ninth Circuit, 2015)
Uthe Technology Corp. v. Aetrium, Inc.
808 F.3d 755 (Ninth Circuit, 2015)
Bacilio Ruiz Torres v. Mercer Canyons Inc.
835 F.3d 1125 (Ninth Circuit, 2016)
Microsoft Corp. v. Baker
582 U.S. 23 (Supreme Court, 2017)
Zinser v. Accufix Research Institute, Inc.
253 F.3d 1180 (Ninth Circuit, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
B.P. v. Ramesh Balwani, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bp-v-ramesh-balwani-ca9-2021.